738 Spurious Drugs Cases, 528 Put On Back Burner

Jaipur: The previous Congress government was apparently very kind to the traders selling death in name of medicine. The situation was such that during these five years, Dept. to control spurious medicines found 738 medicines to be of substandard grade in sample testing, but legal action was taken and challan presented only in 90 cases.

Laxity was shown in taking action against firms related to 89 medicines which were directly found to be fake in sample test. Of these, investigation of 64 medicines has not been completed till now while complaints filed only in 25 out of 89 cases.

The slow pace of probe during Cong govt points towards a nexus between govt machinery and pharma firms. In previous govt, responsibility of Drugscontrol Dept. was first with Raghu Sharma and later with Parsadilal Meena. However, pace of probe in these cases remained the same.

Related Posts

  • Pharma
  • April 4, 2025
  • 35 views
India’s generic medicines steal the spotlight as US exempts pharma from tariffs

India’s pharma sector has emerged as a big winner amid Trump’s tariff woes, as the US has exempted pharmaceuticals from reciprocal tariffs, recognizing the vital role of India’s generic medicines…

  • Pharma
  • April 3, 2025
  • 127 views
Nifty Pharma soars 3% on exclusion from Trump’s reciprocal tariffs; Sun Pharma, IPCA Labs up 5%

Domestic pharmaceutical players heaved a sigh of relief in trade on April 3, while the other sectors see intense selling pressure, as the White House has excluded pharmaceuticals products from…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s generic medicines steal the spotlight as US exempts pharma from tariffs

India’s generic medicines steal the spotlight as US exempts pharma from tariffs

Is Gujarat’s Health Department Rebelling against PM Modi Government?

Is Gujarat’s Health Department Rebelling against PM Modi Government?

Nifty Pharma soars 3% on exclusion from Trump’s reciprocal tariffs; Sun Pharma, IPCA Labs up 5%

Nifty Pharma soars 3% on exclusion from Trump’s reciprocal tariffs; Sun Pharma, IPCA Labs up 5%

Pharma tariff exemption: Temporary relief, but higher tariffs may be imposed later, warns analyst

Pharma tariff exemption: Temporary relief, but higher tariffs may be imposed later, warns analyst